Transplantation of autologous mesenchymal stem cells for end-stage liver cirrhosis: a meta-analysis based on seven controlled trials.
Transplantation of autologous mesenchymal stem cells for end-stage liver cirrhosis: a meta-analysis based on seven controlled trials.
复制标题
DOI：
10.1155/2015/908275
复制
发表时间：
2015
影响因子：
2
通讯作者：
Liang XH
中科院分区：
文献类型：
--
作者：
Ma XR;Tang YL;Xuan M;Chang Z;Wang XY;Liang XH
背景骨髓间充质干细胞（BM-MSCs）作为再生医学在不同的治疗应用中表现出巨大的潜力。本研究旨在汇总既往临床对照试验，对骨髓间充质干细胞移植治疗终末期肝硬化的有效性进行最新评估。方法. 检索Pubmed、Embase和ClinicalTrial. gov中1990年1月至2014年6月发表的相关研究。进行Meta分析以评估BM-MSCs对肝功能指标的影响，包括终末期肝病模型（MELD）评分、血清白蛋白（g/L）、总胆红素（mg/dl）、凝血酶原浓度（%）和丙氨酸氨基转移酶（ALT）（U/L）。结果BM-MSC治疗至少在移植后半年内可以显着改善终末期肝硬化患者的肝功能，包括MELD评分、血清白蛋白、总胆红素和凝血酶原浓度。结论.骨髓间充质干细胞具有免疫调节功能和向肝细胞分化的潜能，是一种很有前途的肝硬化治疗药物。考虑到现有的证据，这种疗法在改善肝功能方面相对安全有效。然而，如何控制不同的变量以优化治疗效果仍然不清楚。因此，未来的机制研究和临床试验需要这种优化。
Background. The bone marrow-derived mesenchymal stem cells (BM-MSCs) have demonstrated great potential as regenerative medicine in different therapeutic applications. This study aims to pool previous controlled clinical trials to make an update assessment of the effectiveness of BM-MSC transplantation on end-stage liver cirrhosis. Methods. Relevant studies published between January 1990 and June 2014 were searched among Pubmed, Embase, and ClinicalTrial.gov. A meta-analysis was performed to assess the effect of BM-MSCs on liver function indicators, including Models of End-Stage Liver Disease (MELD) score, serum albumin (g/L), total bilirubin (mg/dl), Prothrombin concentration (%), and alanine aminotransferase (ALT) (U/L). Results. BM-MSCs therapy could significantly improve liver function in patients with end-stage liver cirrhosis, in terms of MELD score, serum albumin, total bilirubin, and prothrombin concentration, at least during the half year after transplantation. Conclusions. Due to BM-MSCs' immunomodulatory functions and the potential to differentiate into hepatocytes, they are a promising therapeutic agent to liver cirrhosis. Considering currently available evidence, this therapy is relatively safe and effective in improving liver function. However, how different variables should be controlled to optimize the therapeutic effect is still not clear. Thus, future mechanism studies and clinical trials are required for this optimization.
登录
查看更多内容
影响因子：
13.5
作者：
Higashiyama, Reiichi;Inagaki, Yutaka;Okazaki, Isao
通讯作者：
Okazaki, Isao
影响因子：
4.3
作者：
Pan, Xing-Nan;Zheng, Lian-Qiu;Lai, Xiao-Huan
通讯作者：
Lai, Xiao-Huan
影响因子：
1.1
作者：
Robles, Joseph Delano Fule;Cheuk, Daniel Ka Leung;Chan, Godfrey Chi Fung
通讯作者：
Chan, Godfrey Chi Fung
DOI：
10.1016/j.bpg.2011.02.009
发表时间：
2011-04-01
影响因子：
3.2
作者：
Pinzani, Massimo;Rosselli, Matteo;Zuckermann, Michele
通讯作者：
Zuckermann, Michele
影响因子：
64.8
作者：
Vassilopoulos, G;Wang, PR;Russell, DW
通讯作者：
Russell, DW